Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

SBRA vs DEA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SBRA Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 8–2 Matrix Metrics)

SBRA Overall Winner 6-Pillar Tally: SBRA 4 – 2 DEA Matrix Metrics: SBRA 8 – 2 DEA

As of Nov 17, 2026, Sabra Healthcare REIT, Inc. (SBRA) is the stronger overall head-to-head candidate over Easterly Government Properties, Inc. (DEA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). SBRA carries a Unified Composite Score of 57.4/100 (HOLD) at $20.27 (30.4x Forward P/E, 18.4% operating margin), whereas DEA carries 45.1/100 (HOLD) at $21.76 (46.1x Forward P/E, 25.2% operating margin).

  • Technical & Structure Timing Caution: SBRA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 50.8); meanwhile DEA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SBRA vs DEA
SBRA NASDAQ Head-to-Head Winner
Sabra Healthcare REIT, Inc.
Real Estate Investment Trusts
$20.27
-0.37% 1D
Market Cap $5.4B
TTM Revenue $924M
Forward P/E 30.4x
Beta / 30D Vol 0.00β · 30% Vol
Unified Composite Score
57.4 / 100 HOLD
Tech 49.0 Fund 57.0 Flow 57.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 50.8 · SMA20: $20.21 · SMA50: $19.86
DEA NYSE
Easterly Government Properties, Inc.
Real Estate Investment Trusts
$21.76
-0.59% 1D
Market Cap $1.1B
TTM Revenue $371M
Forward P/E 46.1x
Beta / 30D Vol 0.31β · 26% Vol
Unified Composite Score
45.1 / 100 HOLD
Tech 42.0 Fund 52.0 Flow 57.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.6%), weak momentum, RSI 38
RSI-14: 38.3 · SMA20: $22.48 · SMA50: $22.80

6-Pillar Scorecard Institutional Category Breakdown (SBRA 4 – 2 DEA)

Columns: Metric · SBRA · DEA
1. Valuation Multiples SBRA
Forward P/E 30.4x 46.1x
Trailing P/E 75.7x 76.1x
PEG Ratio 5.28x N/M
EV / Revenue 8.4x 7.4x
2. Growth & Scale SBRA
Revenue Growth (YoY) +31.6% +8.8%
Earnings Growth (YoY) +22.2% +450.0%
TTM Revenue (USD) $924M $371M
Market Cap $5.4B $1.1B
3. Profitability & Quality DEA
Gross Margin 49.6% 67.5%
Operating Margin 18.4% 25.2%
Net Profit Margin 7.7% 3.9%
Return on Equity (ROE) 2.5% 1.1%
4. Balance Sheet & Cash Flow SBRA
Cash Generation (TTM) $401M $161M
Cash Flow Margin 43.3% 43.4%
Net Cash / Leverage $2.42B Net Debt (0.86x D/E) $1.67B Net Debt (1.28x D/E)
Dividend Yield 5.92% 8.18%
5. Options & Positioning SBRA
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 27.4% (17th %ile) 34.7% (8th %ile)
Put/Call OI Skew 0.19x (Call-Skewed) 4.08x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat DEA
OpEx & R&D Intensity 31.2% of Rev ($288M) 42.3% of Rev ($157M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Scale & Operating Efficiency Moat
Supply-Chain Role REIT - Healthcare Facilities Operator REIT - Office Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SBRA (8) vs DEA (2)
Institutional Metric SBRA DEA Criterion Row Edge
Market Capitalization
Scale
$5.4B $1.1B Larger Scale SBRA
Trailing P/E Ratio
Valuation
75.7x 76.1x Lower Multiple SBRA
Forward P/E Ratio
Valuation
30.4x 46.1x Lower Multiple SBRA
Revenue Growth (YoY)
Growth
+31.6% +8.8% Higher Growth SBRA
Operating Margin (TTM)
Profitability
18.4% 25.2% Higher Margin DEA
Net Profit Margin
Profitability
7.7% 3.9% Higher Margin SBRA
Return on Equity (ROE)
Capital Efficiency
2.5% 1.1% Higher ROE SBRA
52-Week Range Position
Momentum
52% ($18–$23) 22% ($21–$26) Stronger Trend SBRA
Beta / 30D Volatility
Risk Regime
0.00β · 30% Vol 0.31β · 26% Vol Lower Realized Risk DEA
Unified Institutional Score
Composite Signal
57.4 / 100 (HOLD) 45.1 / 100 (HOLD) Higher Composite SBRA
Trailing 12M Revenue (USD)
Operating Scale
$924M $371M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
49.6% 67.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
5.28x PEG · 8.4x EV/Rev N/M PEG · 7.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$401M ($2.42B Net Debt (0.86x D/E)) $161M ($1.67B Net Debt (1.28x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SBRA +4.91 pp
SBRA: +6.26% · DEA: +1.35%
3M Horizon SBRA +9.57 pp
SBRA: -1.29% · DEA: -10.86%
6M Horizon SBRA +4.26 pp
SBRA: -3.5% · DEA: -7.76%
1Y Horizon SBRA +7.92 pp
SBRA: +8.71% · DEA: +0.79%

Financial Trajectory Annualized Quarterly Run-Rate Revenue & Operating Margin Trajectory (USD-Normalized)

Split-Invariant USD Revenue & Operating Margin (%)
Period SBRA Revenue DEA Revenue SBRA Op. Margin DEA Op. Margin Margin Leader
Q3 '25 $760M $340M 31.3% 25.0% SBRA
Q4 '25 $850M $350M 30.5% 25.0% SBRA
Q1 '26 $890M $370M 30.8% 22.5% SBRA
Q2 '26 $940M $370M -13.6% 24.4% DEA
Q3 '26 $1.00B $370M 25.6% 26.0% DEA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SBRA CONSOLIDATION
80d in phase · OBV DISTRIBUTION
Current IV 27.4%
IV Percentile 17th %ile
Put/Call OI Skew 0.19x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact SBRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DEA CONSOLIDATION
100d in phase · OBV DISTRIBUTION
Current IV 34.7%
IV Percentile 8th %ile
Put/Call OI Skew 4.08x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact DEA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SBRA Moat Profile Scale & Operating Efficiency Moat
REIT - Healthcare Facilities Operator
Competes within the REIT - Healthcare Facilities value chain with $5.4B market capitalization and 18.4% operating margin.
OpEx & R&D Reinvestment 31.2% of Rev ($288M)
90D Engineering Disclosures 0 Published
DEA Moat Profile Scale & Operating Efficiency Moat
REIT - Office Operator
Competes within the REIT - Office value chain with $1.1B market capitalization and 25.2% operating margin.
OpEx & R&D Reinvestment 42.3% of Rev ($157M)
90D Engineering Disclosures 0 Published

Investor FAQ SBRA vs DEA Key Questions & Quantitative Answers

As of Nov 17, 2026, Sabra Healthcare REIT, Inc. (SBRA) is the stronger overall head-to-head candidate over Easterly Government Properties, Inc. (DEA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). SBRA carries a Unified Composite Score of 57.4/100 (HOLD) at $20.27 (30.4x Forward P/E, 18.4% operating margin), whereas DEA carries 45.1/100 (HOLD) at $21.76 (46.1x Forward P/E, 25.2% operating margin). Technical & Structure Timing Caution: SBRA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 50.8); meanwhile DEA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SBRA leads the Growth & Scale pillar: SBRA posts +31.6% YoY revenue growth and +22.2% YoY earnings growth on $924M TTM revenue (49.6% gross margin, 18.4% operating margin), compared with DEA at +8.8% YoY revenue growth and +450.0% YoY earnings growth on $371M TTM revenue (67.5% gross margin, 25.2% operating margin). Across the 5-period historical trajectory (Q3 '25 to Q3 '26), SBRA cumulative revenue shifted +31.6% while DEA shifted +8.8%. In operating R&D and SG&A reinvestment, SBRA deploys 31.2% of Rev ($288M) (0 90-day corporate R&D disclosures) versus 42.3% of Rev ($157M) (0 disclosures) for DEA.

SBRA screens cheaper on headline valuation multiples. SBRA trades at 30.4x Forward P/E, 75.7x Trailing P/E, 5.28x PEG, and 8.4x EV/Revenue (43.3% FCF margin), whereas DEA trades at 46.1x Forward P/E, 76.1x Trailing P/E, N/M PEG, and 7.4x EV/Revenue (43.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SBRA (2.5% ROE) versus DEA (1.1% ROE) capital efficiency.

In options market volatility and institutional positioning, SBRA carries 27.4% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.19x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.00β · 30% Vol realized risk). By comparison, DEA carries 34.7% implied volatility (8th %ile, Compressed (<25th %ile)), a 4.08x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.31β · 26% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.